BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8981406)

  • 21. Conditioned catalepsy vs. Increase in locomotor activity induced by haloperidol.
    De la Casa LG; Cintado MA; González-Tirado G; Cárcel L
    Neurosci Lett; 2023 Apr; 802():137174. PubMed ID: 36906082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haloperidol conditioned catalepsy in rats: a possible role for D1-like receptors.
    Banasikowski TJ; Beninger RJ
    Int J Neuropsychopharmacol; 2012 Nov; 15(10):1525-34. PubMed ID: 22093169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of haloperidol-induced catalepsy in rats by GABAergic neural substrate in the inferior colliculus.
    Tostes JG; Medeiros P; Melo-Thomas L
    Neuroscience; 2013; 255():212-8. PubMed ID: 24125891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents.
    Khisti RT; Deshpande LS; Chopde CT
    Psychopharmacology (Berl); 2002 May; 161(2):120-8. PubMed ID: 11981591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen and haloperidol-induced versus handling-related catalepsy in male rats.
    De Ryck M; Hruska RE; Silbergeld EK
    Pharmacol Biochem Behav; 1982 Nov; 17(5):1027-35. PubMed ID: 7178196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Avian locomotion activated by brainstem infusion of neurotransmitter agonists and antagonists. II. gamma-Aminobutyric acid.
    Sholomenko GN; Funk GD; Steeves JD
    Exp Brain Res; 1991; 85(3):674-81. PubMed ID: 1655510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nicotine potentiates the behavioral effects of haloperidol.
    Emerich DF; Norman AB; Sanberg PR
    Psychopharmacol Bull; 1991; 27(3):385-90. PubMed ID: 1775613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Catalepsy, Fos protein, and dopamine receptor occupancy after long-term haloperidol treatment.
    Coppens HJ; Sebens JB; Korf J
    Pharmacol Biochem Behav; 1995; 51(2-3):175-82. PubMed ID: 7667326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease.
    Trevitt J; Vallance C; Harris A; Goode T
    Pharmacol Biochem Behav; 2009 May; 92(3):521-7. PubMed ID: 19463269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haloperidol-induced catalepsy is influenced by calcium channel antagonists.
    Biała G
    Acta Pol Pharm; 2000; 57(3):233-7. PubMed ID: 11143713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of cerebellar dopamine D(3) receptors in modulating exploratory locomotion and cataleptogenicity in rats.
    Shimizu S; Tatara A; Sato M; Sugiuchi T; Miyoshi S; Andatsu S; Kizu T; Ohno Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Apr; 50():157-62. PubMed ID: 24368396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats.
    Jelovac N; Sikiric P; Rucman R; Petek M; Marovic A; Perovic D; Seiwerth S; Mise S; Turkovic B; Dodig G; Miklic P; Buljat G; Prkacin I
    Eur J Pharmacol; 1999 Aug; 379(1):19-31. PubMed ID: 10499368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The local application of a flavonoid, (-)-epicatechin, increases the spiking of globus pallidus neurons in a dose-dependent manner and diminishes the catalepsy induced by haloperidol.
    Alatorre A; Oviedo-Chávez A; Villalobos N; Ríos A; Barrientos R; Querejeta E
    Behav Pharmacol; 2015 Feb; 26(1-2):117-24. PubMed ID: 25503260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerance of haloperidol catalepsy.
    Ezrin-Waters C; Seeman P
    Eur J Pharmacol; 1977 Feb; 41(3):321-7. PubMed ID: 556989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High frequency stimulation of the posterior hypothalamic nucleus restores movement and reinstates hippocampal-striatal theta coherence following haloperidol-induced catalepsy.
    Jackson J; Young CK; Hu B; Bland BH
    Exp Neurol; 2008 Sep; 213(1):210-9. PubMed ID: 18638477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclosomatostatin- and haloperidol-induced catalepsy in Wistar rats: Differential responsiveness to sleep deprivation.
    Ionov ID; Pushinskaya II; Gorev NP; Frenkel DD
    Neurosci Lett; 2018 Sep; 684():72-77. PubMed ID: 29990558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pontine reticular formation is involved in catalepsy produced by cholinergic drugs.
    Elazar Z; Ganchrow D; Paz M
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Aug; 356(2):166-72. PubMed ID: 9272721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nitric oxide donors antagonize N-nitro-L-arginine and haloperidol catalepsy: potential implication for the treatment of Parkinsonism?
    Krzaścik P; Kostowski W
    Pol J Pharmacol; 1997 Aug; 49(4):263-6. PubMed ID: 9437770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gamma-aminobutyric acid and basal ganglia outflow pathways.
    Reavill C; Jenner P; Marsden CD
    Ciba Found Symp; 1984; 107():164-76. PubMed ID: 6094124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity.
    Emerich DF; Zanol MD; Norman AB; McConville BJ; Sanberg PR
    Pharmacol Biochem Behav; 1991 Apr; 38(4):875-80. PubMed ID: 1871200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.